Trial Registered

Newsoara's HPP737 psoriasis trial surfaces in registry, results still unposted

The Phase 2 trial completed in December 2021, but no PASI-75 data have appeared on ClinicalTrials.gov, leaving the oral candidate's efficacy an open question in a psoriasis field crowded with approved biologics and JAK inhibitors.

By AppliedXLJuly 16, 2026Trial NCT07707141

Executive Summary

A Phase 2 trial of Newsoara HYK Biopharmaceutical's oral candidate HPP737 in adult plaque psoriasis has completed enrollment and closed out its data collection, but its primary result on skin-clearance response has not yet appeared publicly.
The study randomized patients across four arms under triple masking, a design built to compare doses rather than simply confirm a single-arm safety signal, testing whether the drug clears psoriasis plaques to a degree comparable with existing oral therapies.
Oral small molecules dominate active development in plaque psoriasis, with several JAK and TYK2 inhibitors already in Phase 3 testing or commercial use, meaning HPP737's readout would need to show a response rate that holds up against an already-validated therapeutic class rather than establish a new one.
Until the trial's actual PASI 75 and PASI 90 response rates surface, HPP737 cannot be placed against its named oral competitors on efficacy, leaving its path forward undefined.

The trial

The study, registered as NCT07707141, tested HPP737 in adults with moderate-to-severe plaque psoriasis, defined by a Psoriasis Area and Severity Index (PASI) score of at least 12, a Physician's Global Assessment of 3 or higher, and body surface area involvement of at least 10 percent. The trial enrolled 123 patients across sites in China under a randomized, triple-masked, four-arm design, and reached its enrollment target in full. It started in March 2021 and reached its primary completion date on December 20, 2021, a trial duration of 292 days. NCT07707141

What it measured

The registered primary endpoint was the proportion of patients achieving at least a 75 percent improvement in PASI score (PASI 75 response) from baseline at Day 85. Secondary endpoints included PASI 90 response at Day 85 and the incidence and severity of adverse events, covering vital signs, physical exam findings, ECG changes, and laboratory abnormalities. No results have posted to ClinicalTrials.gov for either the primary or secondary measures. NCT07707141

The competitive field

Oral small molecules account for the bulk of active development in plaque psoriasis and adjacent inflammatory skin diseases. Takeda's zasocitinib, Bristol-Myers Squibb's deucravacitinib, and Alumis Inc's ESK-001 are each running Phase 3 programs in plaque psoriasis, while AbbVie's upadacitinib and Pfizer's abrocitinib anchor oral JAK-inhibitor programs in related indications such as atopic dermatitis. None of these share HPP737's specific molecular target, which is not identified in the trial record, so HPP737 sits in a modality-precedent tier of 19 oral small-molecule comparators rather than alongside a direct target-matched rival. Approved options already on the market for plaque psoriasis include ustekinumab, tazarotene, and topical corticosteroid and vitamin D combinations, alongside injectable biologics such as risankizumab and brodalumab used in the broader disease landscape.

Sponsor context

Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. runs a pipeline of ten trials, with three currently recruiting, three at unknown status, two completed, and two not yet recruiting. HPP737's psoriasis study is the sponsor's only trial on record for this drug, and it carries no prior terminations.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.